New York-based healthcare investment firm OrbiMed and Swiss dental innovator vVARDIS recently announced a total investment of $85 million in vVARDIS.
The funds will be used to expand the company’s presence in the US market, especially to promote its early cavity treatment technology Curodont? without drilling.
OrbiMed said that $50 million of the funds were recently raised, and the other $35 million was invested as early as February 2025.
“We have seen Curodont’s rapid development in the dental market since our initial investment. It is currently showing real growth momentum.” said Matthew Rizzo, general partner of OrbiMed.
Curodont is a non-invasive treatment product that can reverse early cavity lesions. According to data provided by vVARDIS co-founders and co-CEOs Dr. Haley and Dr. Goly Abivardi, nearly 10% of dental offices in the United States have introduced this treatment, and more than one million teeth have been treated since the beginning of 2024, serving more than 400,000 patients in total.
Curodont received European CE Mark certification in 2012, entered the international market in 2016, and was approved for sale in the United States by the U.S. Food and Drug Administration (FDA) in 2019.
In 2021, dental equipment company Young Innovations began distributing the product in the United States. In September 2024, Henry Schein became the exclusive U.S. distributor of Curodont Repair Fluoride Plus, a non-invasive fluoride product designed to treat early-stage tooth decay.
“We are very excited to expand our investment to support the next stage of vVARDIS’s development,” Rizzo added. “This technology is bringing new ways to change the dental industry.”